# Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524

> **NCT00898820** · — · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 80 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **GENETIC:** gene expression analysis
- **GENETIC:** polymorphism analysis
- **GENETIC:** protein expression analysis

## Key facts

- **NCT ID:** NCT00898820
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2014-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00898820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00898820, "Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00898820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*